Drug Pipeline

zigakibart Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
2
Recruiting
3
Phase 3
1
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-02 NCT06858319
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.		 Trial sites expanded: 15 -> 18 locations
Active Studies by Phase
Phase 3
3
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06858319 Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. Kidney Diseases Recruiting
NCT05852938 A Study of Zigakibart in Adults With IgA Nephropathy IgA Nephropathy Active, Not Recruiting
NCT04573478 Atrasentan in Patients With IgA Nephropathy IgA Nephropathy Active, Not Recruiting
Phase 2
NCT07146906 A Study to Assess the Effects of Zigakibart on IgA Nephropathy. Immunoglobulin A Nephropathy (IgAN) Recruiting
Sponsors Running zigakibart Trials
Novartis Pharmaceuticals (4)
Disease Areas
Chronic Kidney Disease (1)
Get alerts when zigakibart trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free